HUMAN MEDICINES EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR): DUPIXENT, DUPILUMAB, DERMATITIS, ATOPIC, DATE OF AUTHORISATION: 27/09/2017, REVISION: 9, STATUS: AUTHORISED
(AGENPARL) – LONDON (UNITED KINGDOM), sab 23 gennaio 2021 Atopic dermatitis Dupixent was more effective than placebo (a dummy treatment) at reducing the extent and severity of atopic dermatitis in 3 main studies in patients with moderate to severe disease. In the first study, which involved 740 patients, participants were......